Funding · Healthcare & Life Sciences

ZeroHarm Sciences raises ₹65 crore Series A

By Startup Enthusiast · 25 February 2026

What they do

ZeroHarm Sciences makes 100% plant-based health supplements using nano-formulation technology

It raised ₹65 crore ($7.2 million) in Series A funding led by Kotak Alternate Asset Managers

The company plans to build a health platform and expand internationally to the US, UK, and Middle East

ZeroHarm Sciences raised ₹65 crore in Series A funding.
The round was led by Kotak Alternate Asset Managers Limited via its Kotak Life Sciences Fund I, which invested ₹40 crore.
Alkemi Growth Capital, a healthcare and consumer wellness-focused venture fund, participated with ₹25 crore.
The company will use the funds to build a 'Trust over Promise' health platform that demonstrates supplement efficacy through measurable consumer health outcomes.
Funds will also go toward national brand building and international expansion into the USA, UK, and Middle East.
ZeroHarm Sciences also plans to scale its vertically integrated R&D and manufacturing ecosystem.
Cipher-Plexus acted as the exclusive financial advisor for the transaction.

India's nutraceutical market is projected to reach $18 billion by 2025.
The global nutraceutical market is expected to cross $720 billion by 2027.
Recent fundraises in the space include Elevate Now (₹18 crore) and Earthful (₹26 crore).
The company's proprietary nano-formulation technology differentiates it from competitors like Kapiva, Plix, HealthKart, and Wellbeing Nutrition.

ZeroHarm Sciences is a Hyderabad-based vertically integrated nutraceutical company.
It develops 100% plant-based health supplements using proprietary nano-formulation technology.
The technology converts plant-derived nutrients into nano-sized particles to enhance bioavailability and enable controlled release at lower dosages.
The company works with a network of over 10,000 farmers across Northeast India and the Himalayan region for medicinal plant sourcing.
It controls the full value chain from cultivation to nano-processing.
ZeroHarm Sciences has filed and received patents for multiple nano formulations, including turmeric-based phytochemicals, iron folic acid combinations, carotenoid-based eye health solutions, and synbiotic gut health compositions.
Its portfolio includes over 60 SKUs across categories such as diabetes management, heart health, joint care, immunity, gut health, oncology support, women's wellness, and performance nutrition.
Products are sold through its own website, Amazon, Flipkart, and quick commerce platforms.
The company has served over 300,000 customers (3 lakh).

Build a 'Trust over Promise' health platform demonstrating supplement efficacy through measurable consumer health outcomes.
Expand nationally with brand building initiatives.
Enter international markets including the USA, UK, and Middle East.
Scale the vertically integrated R&D and manufacturing ecosystem.

Kotak Alternate Asset Managers Limited (lead) — Manages the Kotak Life Sciences Fund I, which invested ₹40 crore in this round.
Alkemi Growth Capital (participated) — Healthcare and consumer wellness-focused venture fund that invested ₹25 crore.

Product: Plant-based health supplements using proprietary nano-formulation technology that improves bioavailability and enables controlled release
Customers: Health-conscious consumers seeking plant-based, scientifically-backed nutritional supplements
How it makes money: Direct-to-consumer sales of premium plant-based nutraceuticals with integrated brand building and international expansion
What sets it apart: Proprietary nano-formulation technology integrating Ayurveda with advanced technology for superior bioavailability at lower dosages